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C olorectal cancer is a major cause of cancer mor-tality worldwide,  and the number of deaths from 
colorectal cancer is increasing [1].  Endoscopic treat-
ment for early-stage colorectal cancer has been revealed 
to be effective in reducing this cancer’s progression [2] 
and associated mortality rates [3].
Endoscopic treatment for colorectal tumors first 
started as snare polypectomy [4] and progressed to 
endoscopic mucosal resection (EMR).  EMR was 
reported by Deyhle to be effective in the treatment of 
flat-type colorectal cancer [5],  and the EMR technique 
was developed and became popular during the 1970s.  
EMR is considered a highly effective and minimally 
invasive treatment for gastrointestinal tumors,  and it is 
still widely performed worldwide [6].
However,  in some patients with colorectal cancer,  
the mass cannot be removed in an en bloc fashion with 
only one session of EMR,  as in lesions ≥ 20 mm in size,  
lesions on flexure or on a semilunar fold (tortuous fold),  
and locally recurrent lesions.  These lesions are incom-
pletely resected by means of EMR [7].  The local recur-
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Several reports discussed colonoscopic surveillance after polypectomy and endoscopic mucosal resection 
(EMR) for colorectal polyps,  but only a few reports focused on prognostic analyses,  and none involved meta-
chronous neoplasia after colorectal endoscopic submucosal dissection (ESD).  We conducted the present study 
to assess the risk of adenoma recurrence requiring endoscopic treatment,  and to establish appropriate post-ESD 
colonoscopic surveillance.  We enrolled 116 patients who had undergone colorectal ESD at Okayama University 
Hospital between February 2008 and July 2014 and had been followed-up > 12 months.  We retrospectively ana-
lyzed clinicopathological features of 101 lesions from 101 patients.  Metachronous adenomas were detected in 
21 cases (20.8%).  We divided the patients into 2 groups according to the occurrence of metachronous adeno-
mas.  Our comparison of clinicopathological characteristics between these groups showed that in the metachro-
nous adenomas group the number of synchronous adenomas at index colonoscopy was high and the rate of lat-
erally spreading tumor-nongranular (LST-NG) was higher.  A multivariate analysis indicated that the number of 
synchronous adenomas was significantly associated with metachronous adenomas (HR: 2.54,  95%CI: 1.04-
6.52,  p< 0.05).  The colonoscopic surveillance planning after colorectal ESD should be more meticulous for 
patients with more synchronous adenomas.
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rence rate after endoscopic piecemeal mucosal resection 
(EPMR) is known to be significantly higher than that of 
EMR [8].  En bloc resection is an important technique 
for the accurate pathological diagnosis of a resected 
specimen,  and the use of en bloc resection reduces local 
recurrence and increases the curative resection rate.
Endoscopic submucosal dissection (ESD) was first 
developed for the precise resection of early gastric can-
cers in the 2000s [9 , 10].  ESD has been adopted at sev-
eral institutions for large colorectal tumors,  and it was 
approved for governmental health insurance coverage in 
Japan in 2010 [8].  The ESD technique improved the 
curative resection rate and provided accurate histologi-
cal assessments even with large tumors,  difficult loca-
tions,  and the presence of severe scarring.
Several guidelines for post-polypectomy colonos-
copic surveillance are available,  including those from 
the American Gastroenterological Association (AGA) 
[11] and the European Society of Gastrointestinal 
Endoscopy (ESGE) [12].  However,  these guidelines 
mainly describe surveillance colonoscopy after EMR,  
and the appropriate follow-up policy after colorectal 
ESD has not been established.
The number of reports about treatment outcomes of 
colorectal ESD is increasing.  Most of these reports 
present short-term results,  such as those regarding en 
bloc resection,  local recurrence,  and complication rates 
[13-15].  To the best of our knowledge,  our present 
study provides the first report about the rate of meta-
chronous neoplasia after colorectal ESD.  We conducted 
this study to assess the risk of not only local recurrence 
but also that of metachronous adenomas that require 
resection after colorectal ESD,  and to investigate what 
an appropriate post-ESD colonoscopic surveillance pro-
tocol would be.
Patients and Methods
Patients and eligibility criteria. At our hospital,  
the indications for colorectal ESD are based on the 
Criteria of Indications for Colorectal ESD proposed by 
the Colon ESD Standardization Implementation 
Working Group in Japan [16].  These indications are:  
colorectal epithelial neoplasia,  an endoscopically con-
firmed laterally spreading tumor (LST),  or a polypoidal 
mass > 20 mm in dia.
Initially,  we collected a total of 225 patients who had 
undergone ESD for colorectal tumors at Okayama 
University Hospital between February 2008 and July 
2014.  However,  among them,  109 patients had not 
reached our study’s minimum follow-up period of > 12 
months.  Further analyses in this study were thus done 
for the 116 patients with a follow-up period >12 months.
Of this cohort of 116 patients,  we excluded 15 
patients for the following reasons: (i) residual or locally 
recurrent lesions after endoscopic treatment (n = 7),  (ii) 
additional surgery after ESD (n = 2),  (iii) the presence 
of familial adenomatous polyposis (FAP) (n = 2),  ser-
rated polyposis (n = 1),  (iv) a history of surgery for 
advanced colorectal cancers (n = 2),  and (v) a history of 
ulcerative colitis (n = 1) (Fig. 1).
Consequently,  we retrospectively analyzed the clin-
icopathological features of 101 lesions from 101 patients 
who had undergone ESD.  The analyzed parameters 
included the patients’ gender and age,  the tumor loca-
tion,  tumor size,  macroscopic type,  histological type,  
number of synchronous adenomas at initial colonos-
copy,  follow-up period after ESD,  existence of local 
recurrence during the follow-up period,  and the num-
ber of metachronous adenomas observed at colonos-
copy during the follow-up period.
Three patients had 2 lesions that were simultane-
ously treated with ESD.  We defined the larger lesion of 
the 2 tumors as the main lesion.  In one of these 
patients,  the 2 lesions were almost of the same size,  and 
we considered the lesion with more malignant potential 
as the main lesion.
The tumor locations were classified as right colonic 
(from the cecum to the transverse colon),  left colonic 
(from descending colon to sigmoid colon),  or rectal.  
The tumor size was estimated from the endoscopic 
reports.  The length of the major axis of resected speci-
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Recruitment: 116 patients
Excluded: 15 patients
Reasons for exclusion
•  Locally recurrent lesions: 7 patients
•  ESD + additional curative surgical resection: 2 patients
•  Others
Familial adenomatous polyposis: 2 patients
Serrated polyposis: 1 patient.
Multiple colectomies: 2 patients
Ulcerative colitis: 1 patient
Eligible patients: 101
Fig. 1　 Flow chart of the ESD patient enrollment.
mens,  as measured by the colonoscopist,  was used as 
the tumor size.
The macroscopic classification was based on the 
Paris-Japanese and Kudo classifications [8].  The tumors 
were classified as either laterally spreading tumor gran-
ular type (LST-G),  or LST nongranular type (LST-NG).  
The macroscopic classifications are illustrated in Fig. 2 
[8 , 16].
LST-Gs and LST-NGs are generally subclassified into 
the following subtypes : the homogenous type 
(LST-GH),  nodular mixed type (LST-GM),  flat ele-
vated type (LST-NGF),  and pseudo-depressed type 
(LST-NGPD) [8 , 16].  In our study,  we did not use these 
subtypes,  because only two patients had lesions of the 
LST-NGPD subtype,  and if we had used this classifica-
tion,  the statistical analysis would have been compro-
mised.
The histological findings were collated from the 
patients’ pathology reports.  The histological classifica-
tion used was: low-grade tubular adenoma,  high-grade 
tubular adenoma,  tubulo-villous adenoma,  sessile ser-
rated adenoma/polyp,  intramucosal cancer,  and sub-
mucosal cancer.
We divided the 101 patients into 2 groups: the 
patients with metachronous adenomas at follow-up 
colonoscopy,  and the patients without metachronous 
adenomas.  We then conducted a subgroup analysis 
stratified by clinicopathological features,  plus a multi-
variate analysis.
Definitions. We used the following terms in this 
study: Synchronous adenoma: Adenomatous polyps 
≥ 6 mm detected and resected endoscopically at the 
same time that the main lesion was treated with ESD,  or 
at the preoperative examination before ESD.  In the 
Japan Gastroenterological Endoscopy Society (JGES) 
guidelines for colorectal ESD/EMR,  resection is recom-
mended for adenomas ≥ 6 mm in size [16].  Following 
these guidelines,  all detected adenomatous polyps 
≥ 6 mm in size were resected at our hospital.  When 
such polyps were detected within 1 year after ESD,  they 
were still categorized as synchronous adenomas,  taking 
into account the risk that they had been overlooked 
earlier.  Metachronous adenoma: Adenomatous polyps 
≥ 6 mm detected and resected endoscopically at fol-
low-up colonoscopy,  ≥ 1 year after the ESD (not includ-
ing local recurrence).
ESD procedure. All patients underwent high- 
quality colonoscopy (an index colonoscopy) at enrol-
ment.  All procedures were performed by 1 of 4 highly 
experienced board-certified endoscopists at Okayama 
University Hospital who had each previously performed 
> 30 ESDs.
Conscious sedation was maintained for the entire 
duration of each ESD procedure by administering intra-
venous midazolam (2-3 mg) and pethidine hydrochlo-
ride (35-70 mg).  (Opystan; Mitsubishi Tanabe Pharma,  
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Subtypes of LST Classiﬁcation in type 0
LST Granular (LST-G)
Homogenous type 0-IIa
Nodular mixed type 0-IIa, 0-IIa+Is, Is+0-IIa
LST non-Granular (LST-NG)
Flat elevated type 0-IIa
Pseudo-depressed type 0-IIa+0-c, 0-IIc+0-IIa
LST Granular (LST-G) LST non-Granular (LST-NG)
Homogenous type Nodular mixed type Flat elevated type Pseudo-depressed type
Fig. 2　 Subtypes of laterally spreading tumors (LSTs) and their correspondence in the Paris-Japanese classiﬁcation.  LSTs were deﬁned 
as lesions ＞10 mm in dia.  with a low vertical axis extending laterally along the luminal wall.  LSTs were classiﬁed as either granular type 
(LST-G) or nongranular type (LST-NG).  The LST-Gs and LST-NGs were subclassified into the following subtypes:  
homogenous type (LST-GH),  nodular mixed type (LST-GM),  ﬂat elevated type (LST-NGF),  and pseudo-depressed type (LST-NGPD).  The 
LST subclassiﬁcation in relation to the macroscopic classiﬁcation is shown [8 ,24].
Osaka,  Japan).  Carbon dioxide was used for insuffla-
tion.  A single-channel gastroscope (GIF 260,  260J,  
Q240Z; Olympus,  Tokyo,  Japan) and a colonoscope 
(PCF260AI,  260J,  240ZI,  and Q260AZI; Olympus) 
were used for the rectal and colonic ESD,  respectively.  
Electrosurgical knives and a high-frequency automated 
electrosurgical generator (ICC200 or VIO300; Erbe 
Elektromedizin,  Tübingen,  Germany) in endocut or 
forced coagulation modes were used.
After a submucosal injection of glycerol (Chugai 
Pharma,  Tokyo,  Japan),  a circumferential incision was 
made in the mucosa using a B-Knife® (Xemex,  Tokyo,  
Japan),  or DualKnife® (Olympus).  A mixture of glyc-
erol containing a small amount of indigo carmine dye 
and sodium hyaluronate acid solution (Mucoup®;  
Johnson & Johnson,  New Brunswick,  NJ,  USA) was 
then injected into the submucosal layer to lift the lesion.  
The thickened submucosal layer was incised using a 
B-knife®,  Dual-Knife®,  Mucosectom® (Pentax,  Tokyo,  
Japan),  or SB knife®  (Sumitomo Bakelite,  Tokyo,  Japan).
Follow-up colonoscopy. The first follow-up colo-
noscopy was usually performed 6 or 12 months after 
ESD,  and once every 1-2 years thereafter to assess the 
presence/absence of local recurrence and metachro-
nous adenomas.  The time interval between follow-up 
colonoscopies was decided by each endoscopist after 
considering the patient’s histological findings.
During the follow-up colonoscopy,  the endoscopist 
documented the locations and sizes of all detected 
lesions,  and categorized them as neoplastic or 
non-neoplastic lesions using chromoendoscopy,  narrow 
band imaging,  and magnifying chromoendoscopy.
If the lesions were identified as adenomatous polyps 
≥ 6 mm in dia.,  a hot biopsy,  snare polypectomy,  or 
EMR was performed,  and all resected specimens were 
examined histologically.
Histological assessment. All resected specimens 
were retrieved,  fixed in 10% buffered formalin solution,  
and examined histologically after hematoxylin and eosin 
staining.  The specimens were cut longitudinally into 
2-mm-wide sections that were evaluated microscopi-
cally regarding the resected margin status and tumor 
characteristics including size,  histological type,  depth 
of invasion,  and vascular and lymphatic invasions.
All histological diagnoses were based on the World 
Health Organization classification system [18],  and 
measurements of tumor invasion depth were obtained 
according to the guidelines of the Japanese Society for 
Cancer of the Colon and Rectum (JSCCR) [19].
Statistical analysis. We used the Chi-square test 
or Fisher’s exact test to compare categorical data 
(patient gender and age,  tumor location,  tumor size,  
macroscopic type,  histological type,  number of syn-
chronous adenomas at initial colonoscopy,  follow-up 
period after ESD,  existence of local recurrence during 
the follow-up period,  and the number of metachronous 
adenomas observed at colonoscopy during the fol-
low-up period) between the 2 patient groups.  In the 
multivariate analysis,  we performed a proportional 
hazards test to analyze each tumor’s size and macro-
scopic type and the number of synchronous adenomas 
at index colonoscopy.
The significance level was set at p < 0.05.  The statis-
tical analyses were performed using the JMP 10.0 soft-
ware package for Windows (SAS,  Cary,  NC,  Japan).
Results
Table 1 summarizes the 101 patients’ baseline char-
acteristics.  The median follow-up period was 30.1 
months (range 12-82.9 mos. ).  The median number of 
follow-up colonoscopies was 2 (range 1-5).  The average 
patient age was 68.2 ± 10.0 years.  Sixty-one patients 
(60.4%) were men,  and the other 40 were women 
(39.6%).
Forty-eight lesions (47.5%) were right colonic,  25 
(24.8%) were left colonic,  and 28 (27.7%) were rectal.  
The median size of the resected tumors was 35 mm 
(range 15-95 mm).  All lesions were categorized as 
LSTs.  Among these,  66 lesions (65.4%) were of the 
LST-G type,  and the other 35 lesions (34.6%) were of 
the LST-NG type.
The histological types of the tumors were as follows:  
the low-risk group (30 cases,  29.7%),  all of which were 
of the low-grade tubular adenoma type; and the high-
risk group (71 cases,  71.3%): sessile serrated adenoma/
polyp,  2 cases (1.9%); high-grade tubular adenoma,  
18 cases (17. 8%); tubulo-villous adenoma,  12 cases 
(11.8%); intramucosal cancer,  33 cases (32.6%); and 
SM1 (submucosal invasion < 1,000 μm from muscularis 
mucosae) type,  6 cases (5.9%).
At index colonoscopy,  the median number of syn-
chronous adenomas was 2 (range; 1-13),  and they were 
found in 61 cases (61.4%).  Among these cases,  syn-
chronous adenomas were detected within 1 year after 
ESD in 19 cases.  If all 19 of these polyps are considered 
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missed cases,  the rate of missed adenomas was 18.8% 
(19/101).
Metachronous adenomas after ESD were detected in 
21 cases (20.8%),  whereas local recurrence was detected 
in only 1 case (0.99%).  Fig. 3 provides the Kaplan-Meier 
curve for the cumulative occurrence rate of metachro-
nous adenomas after ESD.  The 3- and 5-year cumula-
tive occurrence rates of metachronous adenomas were 
23.0% and 39.0%,  respectively.
Our comparison of the clinicopathological charac-
teristics of the 2 patient groups divided according to the 
metachronous occurrence versus non-occurrence of 
adenomas revealed that in the metachronous occur-
rence group,  the number of synchronous adenomas at 
index colonoscopy was significantly higher (p = 0.02) 
and the rate of LST-NG was significantly higher 
(p < 0.01) compared to the group without metachronous 
occurrence (Table 2).
The univariate analysis indicated that the following 
were associated with the metachronous occurrence of 
adenomas: tumor size < 35 mm (hazard ratio [HR] 
2.49,  95% confidence interval (CI) 1.03-6.57,  p= 0.042),  
macroscopic type (LST-NG) (HR 2.49,  95%CI 1.04-
6.32,  p = 0.039),  and number of synchronous adenomas 
( ≥ 3) (HR 3.08,  95%CI 1.29-7.83,  p = 0.0108).  The 
multivariate analysis indicated that the number of syn-
chronous adenomas analyzed at index colonoscopy was 
significantly associated with metachronous adenomas 
(HR 2.54,  95%CI 1.04-6.52,  p < 0.05) (Table 3).
All of the recurrent tumors,  including local recur-
rence,  were treated with endoscopic resection.  Curative 
resections were achieved in all cases.
Discussion
In the National Polyp Study (NPS) conducted in the 
United States,  Winawer et al.  reported that colorectal 
cancer can be prevented by the endoscopic removal of 
adenomatous polyps [2].  In another study,  Zauber et al.  
reported that the endoscopic removal of adenomatous 
polyps can prevent death from colorectal cancer [3].
The AGA and ESGE issued their own guidelines for 
surveillance after endoscopic treatment for colorectal 
adenoma,  and each of these entities’ guidelines recom-
mend that all adenomas should be removed at the initial 
examination.  Most of the cases examined in these 
guidelines were related to snare polypectomy and EMR,  
with only a few cases of colorectal ESD examined 
[11 , 12].
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Table 1　 Baseline clinical and pathological characteristics of the 
patients who underwent ESD
n=101
Men n,  (%) 61 (60.4%)
Age (mean ± SD),  years 68.2±10.0
Tumor characteristics
　Location n,  (%)
　　Right colon 48 (47.5%)
　　Left colon 25 (24.8%)
　　Rectum 28 (27.7%)
　Median tumor size (range),  mm 35 (15-95)
　Macroscopic type n,  (%)
　　LST-G 66 (65.4%)
　　LST-NG 35 (34.6%)
　Histological type n,  (%)
　　Low-risk group
　　Low grade tubular adenoma 30 (29.7%)
　　High-risk group
　　SSA/P 2 (1.9%)
　　High grade tubular adenoma 18 (17.8%)
　　Tubulo-villous adenoma 12 (11.8%)
　　Intramucosal cancer 33 (32.6%)
　　SM1 cancer 6 (5.9%)
Median follow-up period (range),  months 30.1 (12-82.9)
Median number of synchronous adenomas 
analyzed at index colonoscopy (range),  months 2 (1-13)
SD,  standard deviation; LST-G,  laterally spreading tumor granular 
type; LST-NG,  laterally spreading tumor non-granular type; SSA/
P,  sessile serrated adenoma/polyp; SM1,  submucosal invasion 
less than 1,000µm from muscularis mucosae.
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Fig. 3　 Cumulative occurrence rate of metachronous adenomas 
after colorectal ESD.  The Kaplan-Meier curve for the 101 patients 
treated with ESD is shown.  The 3-year cumulative occurrence rate 
of metachronous adenomas was 23.0%,  and the 5-year cumulative 
occurrence rate was 39.0%.
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Table 3　 Results of univariate and multivariate analyses for metachronous occurrence of adenomas
Characteristics
Univariate analysis Multivariate analysis
H.R. 95%C.I. p value H.R. 95%C.I. p value
Sex
　　Femal
　　Male 0.97 0.40-2.56 0.95
Age
1.03 0.98-1.09 0.24
Tumor location
　　Right colon
　　Left colon＋Rectum 0.80 0.33-1.91 0.62
Tumor size (median＝35 mm)
　　≥35 mm
　　＜35 mm 2.49 1.03-6.57 0.04 1.86 0.74-5.09 0.19
Macroscopic type
　　LST-G
　　LST-NG 2.49 1.04-6.32 0.04 1.71 0.68-4.55 0.25
Histological type
　　Low-risk group
　　High-risk group 1.91 0.70-6.65 0.22
Number of synchronous adenomas 
analyzed at index colonoscopy
　　＜2
　　≥3 3.08 1.29-7.83 0.01 2.54 1.04-6.52 0.04
LST-G,  laterally spreading tumor granular type; LST-NG,  laterally spreading tumor non-granular type; C.I.,  95% conﬁdence interval; H.R.,  
hazard ratio.
Table 2　 Comparison between clinicopathological characteristics of the groups according to metachronous occurrence of adenomas
With Metachronous 
adenomas
Without Metachronous 
adenomas
n=21 (%) n=80 (%) p value
Male sex n,  (%) 14 (66.7) 47 (58.7) 0.51
Age (mean ± SD),  years 69.0±7.6 68.0±10.6 0.73
Tumor characteristics
　Location n,  (%)
　　Right colon 11 (52.4) 37 (46.3) 0.62
　　Left colon＋Rectum 10 (47.6) 43 (53.7)
　Median tumor size (range),  mm 30 (15-62) 37 (15-95) 0.06
　Macroscopic type n,  (%)
　　LST-G 8 (38.1) 58 (72.5) ＜0.01
　　LST-NG 13 (61.9) 22 (27.5)
　Histological type n,  (%)
　　High-risk group 17 (80.9) 54 (67.5) 0.23
　　Low-risk group 4 (19.1) 26 (32.5)
Median follow-up period (range),  months 20 (12-70) 23 (12-83) 0.88
Median number of synchronous adenomas
　analyzed at index colonoscopy (range),  n 3 (1-9) 2 (1-13) 0.02
SD,  standard deviation; LST-G,  granular laterally spreading tumor; LST-NG,  non-granular laterally spreading tumor.
The JSCCR published its own guidelines for the 
treatment and follow-up of colorectal cancer.  In its 
guidelines concerning the follow-up strategy after 
endoscopic resection,  mainly local recurrence is 
described,  and metachronous lesions of the colon are 
not extensively described [19].
ESD allows clinicians to freely determine the hori-
zontal cutting line,  and to visually confirm the vertical 
cutting line in the submucosal layer,  so that large 
lesions can be resected en bloc fashion with certainty.  
As mentioned in the Introduction,  the local recurrence 
rate after ESD has been much lower than that after 
EMR.  The recommendations regarding surveillance 
plans after colorectal ESD should thus be reviewed and 
updated.
There are few previous reports about surveillance 
after colorectal ESD or studies focusing on large 
(≥ 20 mm dia.) colorectal lesions,  and thus our present 
findings will be useful in the context of establishing 
appropriate post-ESD colonoscopic surveillance.
Although there are slight differences among the 
studies,  the rates of local recurrence for en bloc resec-
tion with EMR and piecemeal resection were reported 
as 4.0% (0-17.9%) and 17.0% (4.8-31.4%),  respectively 
[8].  The latter rate is significantly higher than the for-
mer.  In our study,  the local recurrence rate was 0.99% 
(1/101),  which does not differ from the previous 
reports about colorectal ESD (0-11%) [8].
On the other hand,  in the present study the 5-year 
cumulative occurrence rate of metachronous adenomas 
after colorectal ESD was 39.0%,  which was much higher 
than the local recurrence rate.  This metachronous 
recurrence rate was relatively lower than that described 
in previous reports [20].  The main reason for this dif-
ference would be that the median follow-up period in 
our study was 30.1 months,  which was shorter than that 
in the other studies,  such as the NPS [2].
In previous investigations,  the risk factors for meta-
chronous adenomas after endoscopic treatment for 
colorectal adenoma or early colorectal cancer included 
the size and pathological findings of the main lesion at 
the index colonoscopy,  the number of synchronous 
adenomas,  male gender,  right hemi-colonic location,  
and older age [21].  In our study,  only the number of 
synchronous adenomas analyzed at the index colonos-
copy represented a significant risk factor for metachro-
nous adenomas.
Although our analyses revealed no significant differ-
ences between the different pathologies,  metachronous 
adenomas tended to occur more in the high-risk histol-
ogy group.  This finding may change with the accumu-
lation of future cases.
The results from our study were different from those 
of previous reports about surveillance after polypec-
tomy with regard to the size of the main lesion.  Lesions 
that were not resectable by conventional EMR were 
included in our study; in addition,  LST-NGPDs (which 
have a high frequency of submucosal invasion,  even as 
small tumors [8]) were also included.  Consequently,  
the impact of tumor size on the occurrence of meta-
chronous adenomas was reduced in our study com-
pared to previous reports.
The NPS showed that the first post-polypectomy 
surveillance could be deferred for 3 years [2],  and 
guidelines published by a gastrointestinal consortium in 
1997 recommended that the first follow-up surveillance 
should be performed 3 years after polypectomy for most 
patients.  In 2003,  these guidelines were updated,  and a 
stratification at index colonoscopy into low risk and high 
risk for metachronous adenomas was suggested [22].
The Japan Polyp Study also showed that the first 
post-polypectomy surveillance could be deferred for 3 
years in patients who have undergone complete colo-
noscopies for the control of colorectal cancer twice,  
with removal of all detected polyps [23 , 24].  In 2014,  
the JGES guidelines for colorectal ESD/EMR were pub-
lished [16].  These guidelines state that no optimal 
examination interval for the detection of metachronous 
colorectal tumors has been established,  but that a colo-
noscopy should be carried out within 3 years after 
endoscopic treatment.
On the other hand,  Oka et al.  reported that in their 
multicenter retrospective cohort study,  51% of the 
metachronous index lesions (defined as large adeno-
matous polyps ≥ 10 mm,  intramucosal cancer,  and 
invasive cancer) were newly detected within 3 years,  
and that metachronous submucosal invasive cancer was 
detected in seven cases in the first 12 months [20],  
denoting that a certain number of these index lesions 
were missed at the index colonoscopy.
In our study,  the median follow-up period of the 
patients in whom metachronous adenomas were detected 
was 20 months (range 12-70 months.).  Pathologically,  
most of the metachronous lesions were adenomas,  with 
some intramucosal adenocarcinomas as the most 
aggressive type.  As mentioned above,  local recurrence 
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was detected in only 1 patient (0.99%).  Curative endo-
scopic resections were achieved for all metachronous 
adenomas and locally recurrent lesions.  Based on these 
results,  performing a follow-up colonoscopy at 20 
months after colorectal ESD seems reasonable.
Most of the prior reports about colorectal ESD 
focused on short-term results,  such as the rate of local 
recurrence [14 , 15 , 17].  However,  the rate of local 
recurrence of ESD cases has been very low in compari-
son to that of EMR or EPMR cases,  and the metachro-
nous recurrence rate has been relatively higher than the 
local recurrence rate.  Accordingly,  more attention 
should be given to metachronous adenomas rather than 
local recurrences when performing follow-up colonos-
copies for patients after ESD.
This study has several limitations.  It was a retro-
spective,  single-institution analysis.  Data about the 
patients’ lifestyle and comorbidities as hypertension,  
diabetes mellitus and hyperlipidemia were not collected.  
In addition,  submucosal invasive cancers requiring sur-
gical intervention were not included.
In conclusion,  with regard to the tumor recurrence 
risk after colorectal ESD,  more attention should be 
given to metachronous adenomas occurring at other 
sites rather than local recurrences.  Colonoscopic sur-
veillance after colorectal ESD should be performed 
within 20 months after colorectal ESD,  and more atten-
tion should be given to patients in whom the number of 
synchronous adenomas is 3 or more.  Prospective ran-
domized studies enrolling a larger number of cases 
should be conducted to test our present findings.
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